Posted by Michael Wonder on 21 Oct 2022
Leo Pharma announces European Commission approval of Adtralza (tralokinumab) for the treatment of moderate to severe atopic dermatitis in adolescents
20 October 2022 - Adtralza, a biologic that targets and neutralises the interleukin-13 cytokine, is now approved in Europe for adolescents with moderate to severe atopic dermatitis.
Leo Pharma today announced that the European Commission has extended the marketing authorisation for Adtralza (tralokinumab) to include adolescents aged 12 to 17 with moderate to severe atopic dermatitis who are candidates for systemic therapy.
